Protonix (Pantoprazole)
pantoprazole sodium
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Short-term treatment of erosive esophagitis (EE) associated with GERD | Adults + pediatrics ≥5 yrs (oral); ≥3 months (IV) | Monotherapy | FDA Approved |
| Maintenance of healing of erosive esophagitis | Adults | Monotherapy | FDA Approved |
| Pathological hypersecretory conditions (Zollinger-Ellison syndrome) | Adults | Monotherapy | FDA Approved |
Pantoprazole was approved in the United States in 2000 and is one of the most commonly prescribed PPIs, particularly in the hospital setting where the IV formulation is widely used. Unlike omeprazole and esomeprazole, pantoprazole has a narrower set of FDA-approved indications — it is not specifically approved for symptomatic GERD without erosive esophagitis, H. pylori eradication, or NSAID gastroprotection, although it is extensively used for all of these purposes off-label. A key distinguishing feature of pantoprazole is its weaker inhibition of CYP2C19, which makes it the preferred PPI when concomitant clopidogrel therapy is required.
Symptomatic GERD (without EE): Widely used; ACG guidelines recommend an empirical 8-week PPI trial for typical GERD symptoms without alarm features. Evidence quality: High.
H. pylori eradication: Used as part of triple or quadruple therapy regimens; ACG H. pylori guidelines include pantoprazole as an acceptable PPI component. Evidence quality: High.
Stress ulcer prophylaxis (ICU): Commonly used in critically ill patients; the REVISE trial (2024) evaluated pantoprazole vs placebo in mechanically ventilated patients. Evidence quality: High.
NSAID gastroprotection: Co-prescribed with chronic NSAID therapy in at-risk patients. Evidence quality: Moderate.
Dosing
Adult Dosing — By Clinical Scenario
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Healing of erosive esophagitis | 40 mg QD | 40 mg QD | 40 mg/day | Up to 8 weeks; if not healed, additional 8 weeks may be considered Swallow tablet whole with or without food; do not crush, split, or chew |
| Maintenance of healing of EE | 40 mg QD | 40 mg QD | 40 mg/day | Controlled studies did not extend beyond 12 months |
| Zollinger-Ellison syndrome (oral) | 40 mg BID | Individualized | 240 mg/day | Adjust to patient needs; doses up to 240 mg daily have been administered Doses >40 mg/day not studied in hepatic impairment |
| GERD with history of EE (IV) | 40 mg IV QD | 40 mg IV QD | 40 mg/day IV | 7–10 days in adults; up to 7 days in pediatrics ≥3 months; discontinue once oral tolerated Infuse over 15 minutes or inject over ≥2 minutes |
| ZE syndrome (IV) | 80 mg IV q12h | 80 mg IV q8–12h | 240 mg/day IV | Adjust frequency to maintain acid output <10 mEq/h |
Pediatric Dosing
| Indication / Age | Body Weight | Dose | Notes |
|---|---|---|---|
| EE healing (oral, ≥5 yrs) | 15–<40 kg | 20 mg QD | Up to 8 weeks; safety beyond 8 weeks not established |
| EE healing (oral, ≥5 yrs) | ≥40 kg | 40 mg QD | Up to 8 weeks |
| GERD + history of EE (IV, ≥3 months) | See PI for weight-based dosing | Weight-based per PI | Up to 7 days; discontinue once oral tolerated |
Unlike omeprazole and esomeprazole (which should be taken 30–60 minutes before meals for optimal absorption), pantoprazole delayed-release tablets can be taken with or without food. The enteric coating protects the drug from gastric acid degradation regardless of meal timing. This makes pantoprazole particularly convenient for patients who have difficulty adhering to pre-meal dosing. However, the oral suspension granules should not be taken with food — if sprinkled on applesauce, the Cmax and AUC decrease by approximately 51% and 29%, respectively. The suspension should be administered 30 minutes before a meal.
Pharmacology
Mechanism of Action
Pantoprazole is a substituted benzimidazole proton pump inhibitor that irreversibly inactivates the gastric H+/K+-ATPase in parietal cells. Like all PPIs, it is a prodrug that concentrates in the acidic secretory canaliculi, where the low pH converts it to a reactive sulfenamide species. This sulfenamide forms a covalent disulfide bond with cysteine residues on the proton pump, permanently disabling acid secretion until new pump molecules are synthesized. Pantoprazole binds preferentially to cysteine 822, which is located deeper in the proton pump’s transmembrane domain compared with the binding sites of omeprazole. This may contribute to pantoprazole’s more selective binding profile and its lesser inhibitory effect on CYP2C19, which is clinically relevant for drug interactions with clopidogrel.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Enteric-coated tablet; bioavailability ~77%; Tmax ~2.4 h (40 mg); Cmax ~2.4 µg/mL; AUC ~4.8 µg·hr/mL; dose-proportional PK from 10–80 mg | Tablets can be taken with or without food; oral suspension must be taken 30 min before meals (food reduces Cmax by ~51%); does not accumulate with multiple daily dosing |
| Distribution | Vd ~11–24 L (0.15 L/kg); ~98% protein bound (primarily albumin); concentrates in parietal cell canaliculi via acid-trapping | Not removed by hemodialysis due to extensive protein binding; modest AUC/Cmax increase in women (no dose adjustment needed) |
| Metabolism | Hepatic via CYP2C19 and CYP3A4; primary metabolic pathway is demethylation followed by sulfation (inactive metabolites); less potent CYP2C19 inhibitor than omeprazole or esomeprazole | Weaker CYP2C19 inhibition explains minimal impact on clopidogrel activation; CYP2C19 PM: minimal accumulation (≤23%) with once-daily dosing in adults — no adult dose adjustment needed |
| Elimination | t1/2 ~1 h; ~71% excreted in urine (as metabolites); 18% in feces via biliary excretion; <1% unchanged in urine | Short plasma half-life but irreversible pump inactivation provides ≥24 h acid suppression; no dose adjustment for renal impairment including hemodialysis |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | ~12% | Most commonly reported; generally self-limiting; higher than seen with comparator PPIs in some trials |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | ~9% | If persistent or severe, consider C. difficile testing |
| Nausea | ~7% | Generally transient |
| Abdominal pain | ~6% | Evaluate for underlying pathology if persistent |
| Vomiting | ~4% | More common in pediatric populations |
| Flatulence | ~4% | Related to altered gut flora from acid suppression |
| Arthralgia | ~3% | Evaluate for alternative causes if persistent |
| Dizziness | ~2% | Usually self-limiting |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| C. difficile-associated diarrhea | Uncommon; risk increases with duration | Any time during or after therapy | Test stool for C. difficile; discontinue PPI if confirmed; initiate directed antibiotic therapy |
| Hypomagnesemia | Rare; mainly with >1 year use | Months to years | Check serum magnesium; supplement; may lead to secondary hypocalcemia/hypokalemia; consider PPI discontinuation |
| Bone fractures (hip, wrist, spine) | Observational data; risk with long-term high-dose use | Long-term (≥1 year) | Use lowest effective dose; ensure calcium and vitamin D; FDA class-wide warning |
| Severe cutaneous adverse reactions (SJS, TEN, DRESS, AGEP) | Very rare (postmarketing) | Days to weeks | Discontinue immediately; can be fatal |
| Acute interstitial nephritis | Rare (postmarketing) | Weeks to months | Monitor renal function; discontinue PPI |
| Cutaneous or systemic lupus erythematosus | Rare (postmarketing) | Weeks to years | Discontinue PPI; evaluate for systemic involvement |
| Vitamin B12 deficiency | Rare; with >3 years use | Years | Screen B12 in long-term patients; supplement if deficient |
| Fundic gland polyps | Risk increases with >1 year use | Months to years | Generally benign and reversible; use shortest PPI duration |
Pantoprazole may produce false-positive results on urine screening tests for tetrahydrocannabinol (THC). This is unique among PPIs and can cause unnecessary clinical or employment consequences. Confirmatory testing (e.g., GC-MS) should be performed to rule out a true positive. Document pantoprazole use when ordering urine drug screens to avoid misinterpretation.
Drug Interactions
Pantoprazole has a comparatively favorable drug interaction profile among PPIs, primarily because it is a weaker inhibitor of CYP2C19 than omeprazole or esomeprazole. This makes it the preferred PPI when concomitant clopidogrel therapy is clinically necessary. Like all PPIs, it elevates gastric pH and can impair absorption of pH-dependent drugs. Pantoprazole is also metabolized by CYP2C19 and CYP3A4, making it susceptible to strong enzyme inducers.
Monitoring
- Symptom Response4–8 weeks
RoutineReassess need for continued PPI. If no EE or high-risk features, consider step-down, on-demand dosing, or H2RA switch. - Serum MagnesiumPeriodically in long-term use
Trigger-basedHypomagnesemia reported with ≥3 months PPI use. Also consider calcium monitoring in those at risk of hypocalcemia. - INR / PTWhen initiating or stopping pantoprazole in warfarin patients
Trigger-basedCase reports of increased INR with concomitant PPI + warfarin. - Vitamin B12Periodically if >3 years use
Trigger-basedChronic acid suppression impairs cyanocobalamin absorption. - Bone DensityPer osteoporosis guidelines
Trigger-basedFDA class-wide warning; ensure adequate calcium and vitamin D. - Chromogranin AStop PPI ≥14 days before testing
Trigger-basedPPIs elevate CgA, causing false-positive results for neuroendocrine tumors.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to substituted benzimidazoles or any excipient: Includes pantoprazole, omeprazole, esomeprazole, lansoprazole, rabeprazole, and dexlansoprazole.
- Rilpivirine-containing products: Elevated gastric pH drastically reduces rilpivirine absorption.
Relative Contraindications (Specialist Input Recommended)
- Atazanavir or nelfinavir: Do not co-administer — significantly reduced antiviral drug levels.
- Severe hepatic impairment: Doses exceeding 40 mg/day have not been studied; modest accumulation (≤21%) possible.
Use with Caution
- Long-term use without clear indication: Risk of C. difficile, hypomagnesemia, B12 deficiency, fractures, fundic gland polyps, and SCAR.
- Patients at osteoporosis risk: Use lowest effective dose; ensure calcium/vitamin D supplementation.
- Suspected gastric malignancy: Symptomatic improvement does not exclude malignancy.
The FDA issued class-wide warnings for PPIs regarding (1) possible increased risk of hip, wrist, and spine fractures with long-term, high-dose use and (2) severe cutaneous adverse reactions including SJS, TEN, DRESS, and AGEP. Additionally, pantoprazole rodent carcinogenicity studies showed rare gastrointestinal tumors — the FDA label notes this finding, though clinical relevance in humans has not been established. Use the lowest dose and shortest duration appropriate.
Patient Counselling
Purpose of Therapy
Pantoprazole reduces stomach acid to help heal damage to your esophagus and prevent it from returning. It may also be used to treat conditions where the stomach produces too much acid.
How to Take
Swallow the tablet whole with or without food — do not crush, split, or chew it. If using the oral suspension (granules), mix with apple juice or applesauce and take 30 minutes before a meal. For hospital use, pantoprazole may be given intravenously.
Sources
- PROTONIX (pantoprazole sodium) delayed-release tablets / for delayed-release oral suspension. Full Prescribing Information. Wyeth/Pfizer. Revised June 2023. Pfizer PIPrimary reference for oral dosing, indications, adverse reactions, drug interactions, and PK data.
- PROTONIX I.V. (pantoprazole sodium) for injection. Full Prescribing Information. Pfizer. Revised 2024. FDA Label (2024)IV formulation label with pediatric dosing (≥3 months), ZE IV dosing, and thrombophlebitis warnings.
- Metz DC, Bochenek WJ; Pantoprazole US GERD Study Group. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Am J Gastroenterol. 2000;95(11):3071-3080. doi:10.1111/j.1572-0241.2000.03254.xPivotal US trial establishing pantoprazole 40 mg as safe and effective for EE healing (88% at 8 weeks).
- Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther. 2004;20(5):567-575. doi:10.1111/j.1365-2036.2004.02101.xMaintenance trial supporting pantoprazole 40 mg and 20 mg for long-term EE remission.
- Metz DC, Soffer E, Forsmark CE, et al. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol. 2003;98(2):301-307. doi:10.1111/j.1572-0241.2003.07234.xLong-term ZE study demonstrating effective acid control with pantoprazole 80–240 mg/day.
- Cook D, Deane A, Lauzier F, et al. (REVISE Investigators). Stress ulcer prophylaxis during invasive mechanical ventilation. N Engl J Med. 2024;391(1):9-20. doi:10.1056/NEJMoa2404245Landmark trial (pantoprazole vs placebo) in mechanically ventilated ICU patients for stress ulcer prophylaxis.
- Katz PO, Dunbar KB, Schnoll-Sussman FH, et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538Current ACG GERD guideline recommending PPI as first-line therapy for 8 weeks.
- MacLaren R, Dionne JC, Granholm A, et al. SCCM/ASHP Guideline for the prevention of stress-related gastrointestinal bleeding in critically ill adults. Crit Care Med. 2024;52(8):e421-e430. doi:10.1097/CCM.0000000000006359Updated 2024 SCCM/ASHP guideline on stress ulcer prophylaxis with PPIs in the ICU.
- Farrell B, Pottie K, Thompson W, et al. Deprescribing proton pump inhibitors. Can Fam Physician. 2017;63(5):354-364. PMID:28500192Evidence-based PPI deprescribing guideline.
- Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther. 2006;23(Suppl 2):2-8. doi:10.1111/j.1365-2036.2006.02943.xAuthoritative PPI pharmacology review covering cysteine binding site differences between PPIs.
- Shah N, Gossman W. Pantoprazole. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Updated July 2025. NBK499945Comprehensive clinical pharmacology review covering dosing, PK, CYP2C19 polymorphism effects, and monitoring.
- Lima JJ, Thomas CD, Barbarino J, et al. CPIC Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423. doi:10.1002/cpt.2015CPIC pharmacogenomic guideline with CYP2C19 allele-specific PPI dosing recommendations.
- FDA Drug Safety Communication: Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. FDA. Revised March 2011. FDA.govFDA class-wide safety communication on PPI-associated fracture risk.